Abreva
Abreva, licence 80120191: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Haleon Canada ULC
- NPN or DIN-HM
- 80120191
- Status
- Active licence
- Licence date
- 29 July 2022
- Revision date
- 29 August 2022
- Form
- Crème
- Route of administration
- Topique
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Huile minérale légère, Stéarate de saccharose, alpha-D-glucopyranoside, beta-D-fructofuranosyle, dioctadécanoate, Propylène glycol, Eau, Alcool benzylique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants, adolescents et adultes | minimum: 12.0 Année(s) | 1.0 Crème | 5.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Cold Sore Treatment. For the treatment of acute episodes of recurrent oral-facial herpes simplex (fever blisters or cold sores) in adults. Treats cold sores / fever blisters on the lips and face. For the treatment of recurrent cold sores. Abreva is clinically proven to shorten the healing time (duration) of your cold sore. Shortens healing time and the duration of cold sore symptoms including pain, burning, tingling and itching. Reduces the duration of pain, burning, itching and tingling associated with cold sores. Clinically proven to speed cold sore healing. In clinical trials, the time to complete healing was statistically significantly shorter in the Abreva group (4.1 days) than the placebo group (4.8 days). ABREVA demonstrated statistically significant reductions in duration of the oral-facial herpes simplex associated symptoms of pain and/or burning, itching or tingling when compared to placebo. The predominant mechanism for the anti-HSV activity of docosanol appears to be inhibition of fusion between the plasma membrane and the HSV envelope, which helps to treat cold sores. Blocks viral entry into the cell and subsequent viral replication, thereby helping to treat cold sores. Viral Entry Blocking Agent to help treat cold sores. Inhibits entry of the cold sore virus into surrounding cells to help treat cold sores. ABREVA contains docosanol, a substance which blocks the ability of the cold sore virus to enter your skin cells, limiting its ability to spread to surrounding cells and thereby helping to treat cold sores. Abreva soothes cold sores on contact.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80120191
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.